Rob Reistetter

Rob co-founded Iron Path Capital in 2021, co-leads the firm’s private equity execution and leads Iron Path’s internal operations. Prior to founding Iron Path, he was a Principal with Quad-C where he spent nearly 14 years on deal teams that invested over $750 million of equity. Rob was one of two senior professionals that established the healthcare vertical at Quad-C and he also led the specialty chemicals initiative for seven years.  

Rob currently serves on the boards of Emergence Health and Versant Diagnostics.  His investment experience at Quad-C includes companies such as Boulder Scientific Company, Prism Vision Group, Retina Group of Washington, VMG Health, Compassion First, Dental Care Alliance, Towncare Dental, NuSil Technology and Royal Adhesives & Sealants.

Prior to joining Quad-C, he worked at JLL Partners where he evaluated and executed private equity investments in various industries.  Prior to JLL Partners, Rob was with J.P. Morgan Chase in the Leveraged Finance Group where he focused on providing senior and subordinated debt financing for a broad range of leveraged buyout transactions.

Rob holds a B.S. degree in Finance & Accounting from Ithaca College and an M.B.A. from Harvard Business School.